3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
1780
Triple Negative Breast Neoplasms
299
Ovarian Neoplasms
136
Lung Neoplasms
115
Colorectal Neoplasms
115
Neoplasms
106
Prostatic Neoplasms
103
Carcinoma, Non-Small-Cell Lung
101
Neoplasm Metastasis
96
Stomach Neoplasms
81
Pancreatic Neoplasms
78
Melanoma
74
Endometrial Neoplasms
65
Head and Neck Neoplasms
60
Uterine Cervical Neoplasms
56
Squamous Cell Carcinoma of Head and Neck
50
Colonic Neoplasms
45
Esophageal Neoplasms
42
Sarcoma
41
Carcinoma, Intraductal, Noninfiltrating
41
Motor Activity
37
HER2-positive Breast Cancer
34
Urinary Bladder Neoplasms
33
Liver Neoplasms
31
Carcinoma, Renal Cell
30
Brain Neoplasms
28
Advanced Breast Cancer
25
Lymphedema
24
Kidney Neoplasms
24
Carcinoma, Transitional Cell
23
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
Breast
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled